A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ContraVir Pharmaceuticals, Inc.
• Treatments: Hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine

Criteria

Inclusion Criteria:

• Age: 18-55.

• Capable of giving written informed consent.

• Capable of completing study requirements.

Exclusion Criteria:

• Positive result for HIV, HBV, or HCV.

• History or medical condition which could impact patient safety.

• Current or past abuse of alcohol or illicit drugs.

• Participation in another clinical trial within the past 30 days.